L. e A. Seràgnoli Department of Hematology and Oncological Sciences, S. Orsola-Malpighi Hospital, University of Bologna, I-40138 Bologna, Italy.
Oncol Rep. 2010 May;23(5):1183-92. doi: 10.3892/or_00000749.
Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. Hence chemotherapy, possibly combined with radiation therapy, remains the only treatment option aimed at palliation of symptoms and ensuring a better quality of life. Notwithstanding the efforts to find more effective therapies for the treatment of pancreatic cancer, significant results have not yet been achieved. Increasing interest has focused on integrated treatments, i.e. chemotherapy combined with targeted therapies, and a better selection of patients. This study examines the principal clinical trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years.
胰腺导管腺癌是西方世界的第四大死因。手术仍然是唯一提供整体生存优势（5 年生存率范围为 15-25%）的治疗方法，但不幸的是，只有 10-20%的患者在诊断时患有可切除的疾病。因此，化疗，可能联合放射治疗，仍然是唯一的治疗选择，旨在缓解症状并确保更好的生活质量。尽管人们努力寻找更有效的治疗胰腺癌的方法，但尚未取得显著成果。人们越来越关注综合治疗，即化疗联合靶向治疗，以及更好地选择患者。本研究探讨了主要的临床试验，这些试验将帮助临床医生了解近年来晚期胰腺癌患者系统治疗取得的进展。
